These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 12495648)

  • 1. A paradoxical effect of levetiracetam may be seen in both children and adults with refractory epilepsy.
    Nakken KO; Eriksson AS; Lossius R; Johannessen SI
    Seizure; 2003 Jan; 12(1):42-6. PubMed ID: 12495648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Add-on levetiracetam in children and adolescents with refractory epilepsy: results of an open-label multi-centre study.
    Callenbach PM; Arts WF; ten Houten R; Augustijn P; Gunning WB; Peeters EA; Weber AM; Stroink H; Geerts Y; Geerts AT; Brouwer OF
    Eur J Paediatr Neurol; 2008 Jul; 12(4):321-7. PubMed ID: 17950011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-label study of levetiracetam at individualised doses between 1000 and 3000 mg day(-1) in adult patients with refractory epilepsy.
    Abou-Khalil B; Hemdal P; Privitera MD
    Seizure; 2003 Apr; 12(3):141-9. PubMed ID: 12651078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of levetiracetam: an add-on trial in children with refractory epilepsy.
    Grosso S; Franzoni E; Coppola G; Iannetti P; Verrotti A; Cordelli DM; Marchiani V; Pascotto A; Spalice A; Acampora B; Morgese G; Balestri P
    Seizure; 2005 Jun; 14(4):248-53. PubMed ID: 15911359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life, mood and seizure control in patients with brain tumor related epilepsy treated with lacosamide as add-on therapy: A prospective explorative study with a historical control group.
    Maschio M; Zarabla A; Maialetti A; Fabi A; Vidiri A; Villani V; Giannarelli D
    Epilepsy Behav; 2017 Aug; 73():83-89. PubMed ID: 28623754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study.
    Beran RG; Berkovic SF; Black AB; Danta G; Hiersemenzel R; Schapel GJ; Vajda FJ
    Epilepsy Res; 2005 Jan; 63(1):1-9. PubMed ID: 15716083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of 1000-4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy.
    Grant R; Shorvon SD
    Epilepsy Res; 2000 Dec; 42(2-3):89-95. PubMed ID: 11074181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levetiracetam add-on for drug-resistant localization related (partial) epilepsy.
    Chaisewikul R; Privitera MD; Hutton JL; Marson AG
    Cochrane Database Syst Rev; 2001; (1):CD001901. PubMed ID: 11279737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Experience with levetiracetam in childhood epilepsy].
    Neuwirth M; Saracz J; Hegyi M; Paraicz E; Kollár K; Móser J; Rosdy B; Herczegfalvi A; Fogarasi A
    Ideggyogy Sz; 2006 May; 59(5-6):179-82. PubMed ID: 16786712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy.
    Ben-Menachem E; Gilland E
    Seizure; 2003 Apr; 12(3):131-5. PubMed ID: 12651076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of levetiracetam in children with refractory epilepsy as an add-on trial.
    Tonekaboni SH; Ghazavi M; Karimzadeh P; Mahvelati F; Ghofrani M
    Epilepsy Res; 2010 Aug; 90(3):273-7. PubMed ID: 20619606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of levetiracetam: a review of three pivotal clinical trials.
    Privitera M
    Epilepsia; 2001; 42 Suppl 4():31-5. PubMed ID: 11564123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levetiracetam in pediatrics.
    Vigevano F
    J Child Neurol; 2005 Feb; 20(2):87-93. PubMed ID: 15794171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levetiracetam in refractory pediatric epilepsy.
    Wheless JW; Ng YT
    J Child Neurol; 2002 Jun; 17(6):413-5. PubMed ID: 12174960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy.
    Ben-Menachem E; Edrich P; Van Vleymen B; Sander JW; Schmidt B
    Epilepsy Res; 2003 Feb; 53(1-2):57-64. PubMed ID: 12576168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of levetiracetam in refractory childhood epilepsy syndromes.
    Lagae L; Buyse G; Deconinck A; Ceulemans B
    Eur J Paediatr Neurol; 2003; 7(3):123-8. PubMed ID: 12788038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Levetiracetam in the treatment of epilepsy].
    Mariero Klees T; Brodtkorb E; Nakken KO; Lossius R; Johannessen SI
    Tidsskr Nor Laegeforen; 2003 May; 123(11):1539-41. PubMed ID: 12822020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy.
    Betts T; Waegemans T; Crawford P
    Seizure; 2000 Mar; 9(2):80-7. PubMed ID: 10845730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective study of levetiracetam efficacy in epileptic syndromes with continuous spikes-waves during slow sleep.
    Atkins M; Nikanorova M
    Seizure; 2011 Oct; 20(8):635-9. PubMed ID: 21752673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy.
    Li S; Cao J; Xiao N; Cai F
    J Child Neurol; 2010 May; 25(5):609-13. PubMed ID: 19779208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.